Structure via PubChem · Public domain (PubChem)
semaxanib
Sign in to saveAlso known as SU 5416, SU5416, VEGF receptor 2 kinase inhibitor III, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, (Z)-SU 5416, 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole, 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone, TSU 16
Semaxanib (INN, codenamed SU5416) is a tyrosine-kinase inhibitor drug designed by SUGEN as a cancer therapeutic. It is an experimental stage drug, not licensed for use on human patients outside clinical trials. Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.
Chemical data
- Formula
- C15H14N2O
- Molecular weight
- 238.28 g/mol
- IUPAC name
- (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
- SMILES
- CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
- InChIKey
- WUWDLXZGHZSWQZ-WQLSENKSSA-N
- XLogP
- 2.5
- Polar surface area
- 44.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- renal cell carcinoma, mesothelioma, melanoma, cutaneous melanoma
via ChEMBL · EBI
Research
514 papers- Equivalence Study of Semaxanib from Different Suppliers.American journal of respiratory cell and molecular biology · 2020
- Semaxanib, a VEGF inhibitor, suppresses melanogenesis by modulating CRTC3 independently of VEGF signaling.Journal of dermatological science · 2024
- Inactivation of Malic Enzyme 1 in Endothelial Cells Alleviates Pulmonary Hypertension.Circulation · 2024
- Endothelial upregulation of mechanosensitive channel Piezo1 in pulmonary hypertension.American journal of physiology. Cell physiology · 2021
- Semaxanib (SUGEN).IDrugs : the investigational drugs journal · 2001
via PubMed
Wikidata facts
- Mass
- 238.111
- Has use
- medication
Show 7 more facts
- subject has role
- protein kinase inhibitors
- chemical formula
- C₁₅H₁₄N₂O
- isomeric SMILES
- CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
- canonical SMILES
- CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
- World Health Organisation international non-proprietary name
- semaxanib
- Commons category
- Semaxanib
- found in taxon
- Streptomyces
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Research
- Synthesis
- See also
- References
Semaxanib (INN, codenamed SU5416) is a tyrosine-kinase inhibitor drug designed by SUGEN as a cancer therapeutic. It is an experimental stage drug, not licensed for use on human patients outside clinical trials. Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.
==Research==
Excerpted from Wikipedia’s “semaxanib” article, available under the CC BY-SA 4.0 licence.
Available in 6 languages
via Wikidata sitelinks · CC0